This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Popov, V. M. Articles by Pestell, R. G. Search for Related Content PubMed PubMed Citation Articles by Popov, V. M. Articles by Pestell, R. G.

The Cell Fate Determination Factor DACH1 Is Expressed in Estrogen Receptor-–Positive Breast Cancer and Represses Estrogen Receptor- Signaling

¹ Departments of Cancer Biology and Oncology, Kimmel Cancer Center, Thomas Jefferson University; ² Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania; ³ Department of Obstetrics and Gynecology, University of Texas, Health Science Center, San Antonio, Texas; and ⁴ Department of Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Richard G. Pestell, Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107. Phone: 213-503-5692; Fax: 215-503-9334; E-mail: Richard.Pestell{at}jefferson.edu.

Key Words: breast cancer • DACH1, dachshund • estrogen receptor

The Dachshund (dac) gene, initially cloned as a dominant inhibitor of the Drosophila hyperactive EGFR mutant ellipse, encodes a key component of the cell fate determination pathway involved in Drosophila eye development. Analysis of more than 2,200 breast cancer samples showed improved survival by some 40 months in patients whose tumors expressed DACH1. Herein, DACH1 and estrogen receptor- (ER) expressions were inversely correlated in human breast cancer. DACH1 bound and inhibited ER function. Nuclear DACH1 expression inhibited estradiol (E₂)-induced DNA synthesis and cellular proliferation. DACH1 bound ER in immunoprecipitation-Western blotting, associated with ER in chromatin immunoprecipitation, and inhibited ER transcriptional activity, requiring a conserved DS domain. Proteomic analysis identified proline, glutamic acid, and leucine rich protein 1 (PELP1) as a DACH1-binding protein. The DACH1 COOH terminus was required for binding to PELP1. DACH1 inhibited induction of ER signaling. E₂ recruited ER and disengaged corepressors from DACH1 at an endogenous ER response element, allowing PELP1 to serve as an ER coactivator. DACH1 expression, which is lost in poor prognosis human breast cancer, functions as an endogenous inhibitor of ER function. [Cancer Res 2009;69(14):5752–60]